A β-tubulin 5-derived peptide induces cytotoxic T lymphocytes restricted to the HLA-A24 allele in prostate cancer patients

Komatsu,Nobukazu; Terasaki,Yasunobu; Moriya,Fukuko; Suekane,Shigetaka; Noguchi,Masanori; Todo,Satoru; Itoh,Kyogo; Shichijo,Shigeki

doi:10.3892/etm.2010.120

A β-tubulin 5-derived peptide induces cytotoxic T lymphocytes restricted to the HLA-A24 allele in prostate cancer patients

Authors:
- Nobukazu Komatsu
- Yasunobu Terasaki
- Fukuko Moriya
- Shigetaka Suekane
- Masanori Noguchi
- Satoru Todo
- Kyogo Itoh
- Shigeki Shichijo
View Affiliations

Affiliations: Department of Immunology and Immunotherapy, Kurume University School of Medicine, Fukuoka 830-0011, Japan, Department of Urology, Kurume University School of Medicine, Fukuoka 830-0011, Japan, Department of Surgery, Hokkaido University School of Medicine, Hokkaido 060-8638, Japan
Published online on: July 20, 2010 https://doi.org/10.3892/etm.2010.120
Pages: 833-839

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To facilitate the development of a peptide-based cancer vaccine for prostate cancer patients, we examined whether any of the 13 peptides previously reported to induce HLA-class I-restricted cytotoxic T lymphocyte (CTL) activity in HLA-A3 supertype (-A3, -A11, -A31 and -A33)-positive prostate cancer patients are also capable of inducing CTLs restricted to HLA-A2, HLA-A24 or HLA-A26 alleles. Among the 13 peptides tested, a peptide at positions 309 to 318 of β-tubulin 5 exhibited binding activity to the HLA-A*2402 molecule and induced HLA-A24-restricted CTL activity against prostate cancer cells derived from peripheral blood mononuclear cells of prostate cancer patients. The CTL activity was determined to be specific to this peptide and was mediated by CD8+ T cells in an HLA-class I-restricted manner. These results suggest that this peptide could be applicable as a peptide vaccine, not only for HLA-A3 supertype-positive, but also for HLA-A24-positive prostate cancer patients.

View Figures

View References

1.	Noguchi N, Kakuma T, Uemura H, et al: A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother. 59:1001–1009. 2010. View Article : Google Scholar
2.	Terasaki Y, Shichijo S, Nui Y, et al: An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles. Cancer Immunol Immunother. 58:1877–1885. 2009. View Article : Google Scholar : PubMed/NCBI
3.	Mohamed RE, Naito M, Terasaki Y, et al: Capability of SART_3109–118 peptide to induce cytotoxic T-lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles. Int J Oncol. 34:529–536. 2009.
4.	Niu Y, Komatsu N, Komohara K, et al: A peptide derived from hepatitis C virus (HCV) core protein inducing cellular responses in patients with HCV with various HLA class IA alleles. J Med Virol. 81:1232–1240. 2009. View Article : Google Scholar : PubMed/NCBI
5.	Niu Y, Terasaki Y, Komatsu N, Noguchi M, Shichijo S and Itoh K: Identification of peptides applicable as vaccines for HLA-A26-positive cancer patients. Cancer Sci. 100:2167–2174. 2009. View Article : Google Scholar : PubMed/NCBI
6.	Matsueda S, Takedatsu H, Yao A, et al: Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles. Clin Cancer Res. 11:6933–6943. 2005. View Article : Google Scholar : PubMed/NCBI
7.	Takedatsu H, Shichijo S, Katagiri K, Sawamizu H, Sata M and Itoh K: Identification of peptide vaccine candidates sharing among HLA-A3⁺, -A11⁺, -A31⁺, and -A33⁺ cancer patients. Clin Cancer Res. 10:1112–1120. 2004. View Article : Google Scholar : PubMed/NCBI
8.	Minami T, Matsueda S, Takedatsu H, et al: Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles. Cancer Immunol Immunother. 56:689–698. 2007. View Article : Google Scholar : PubMed/NCBI
9.	Matsueda S, Takedatsu H, Sasada T, et al: New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles. J Immunother. 30:274–281. 2007. View Article : Google Scholar : PubMed/NCBI
10.	Naito M, Komohara Y, Ishihara Y, et al: Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles. Br J Cancer. 97:1648–1654. 2007. View Article : Google Scholar : PubMed/NCBI
11.	Yao A, Harada M, Matsueda S, et al: Identification of parathyroid hormone-related protein-derived peptides immunogenic in human histocompatibility leukocyte antigen-A24⁺ prostate cancer patients. Br J Cancer. 91:287–296. 2004.
12.	Torikai H, Akatsuka Y, Miyauchi H, et al: The HLA-A^0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A^0206. Bone Marrow Transplant. 40:165–174. 2007.
13.	Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG and Rickinson AB: Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med. 185:1605–1607. 1997. View Article : Google Scholar : PubMed/NCBI
14.	Lee SP, Tierney RJ, Thomas WA, Brooks JM and Rickinson AB: Conserved CTL epitopes within EBV latent membrane protein 2. A potential target for CTL-based tumor therapy. J Immunol. 158:3325–3334. 1997.PubMed/NCBI
15.	Parker KC, Bednarek MA, Hull LK, et al: Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. J Immunol. 149:3580–3587. 1992.PubMed/NCBI
16.	Ikeda-Moore Y, Tomiyama H, Miwa K, et al: Identification and characterization of multiple HLA-A24-restricted HIV-1 CTL epitopes: strong epitopes are derived from V regions of HIV-1. J Immunol. 159:6242–6252. 1997.PubMed/NCBI
17.	Rammensee HG, Flak K and Rotzschke O: Peptides naturally presented by MHC class I molecules. Annu Rev Immunol. 11:213–244. 1993. View Article : Google Scholar : PubMed/NCBI
18.	Hida N, Maeda Y, Katagiri K, Takasu H, Harada M and Itoh K: A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunother. 51:219–228. 2002. View Article : Google Scholar : PubMed/NCBI
19.	Jordan MA and Wilson L: Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol. 10:123–130. 1998. View Article : Google Scholar : PubMed/NCBI
20.	Hashimoto Y, Tajima O, Hashiba H, Nose K and Kuroki T: Elevated expression of secondary, but not early, responding genes to phorbol ester tumor promoters in papillomas and carcinomas of mouse skin. Mol Carcinog. 3:302–308. 1990. View Article : Google Scholar : PubMed/NCBI
21.	Kato K, Ito H, Inaguma Y, Okamoto K and Saga S: Synthesis and accumulation of αB crystallin in C6 glioma cells is induced by agents that promote the disassembly of microtubules. J Biol Chem. 271:26989–26994. 1996.
22.	Cucchiarelli V, Hiser L, Smith H, et al: Beta-tubulin isotype classes II and V expression patterns in non-small cell lung carcinomas. Cell Motil Cytoskeleton. 65:675–685. 2008. View Article : Google Scholar : PubMed/NCBI